Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Pancreatic Neoplasms 406Carcinoma, Non-Small-Cell Lung 147Urinary Bladder Neoplasms 87Breast Neoplasms 84Cholangiocarcinoma 82Lung Neoplasms 78Neoplasm Metastasis 67Neoplasms 64Biliary Tract Neoplasms 58Nasopharyngeal Carcinoma 53Ovarian Neoplasms 46Sarcoma 43Recurrence 39Gallbladder Neoplasms 39Hodgkin Disease 34Lymphoma, Large B-Cell, Diffuse 33Lymphoma 32Carcinoma, Transitional Cell 29Bile Duct Neoplasms 24Adenocarcinoma 23Fallopian Tube Neoplasms 19Carcinoma, Hepatocellular 19Adenocarcinoma of Lung 18Triple Negative Breast Neoplasms 17Lymphoma, Non-Hodgkin 17Liver Neoplasms 17Nasopharyngeal Neoplasms 16Lymphoma, Extranodal NK-T-Cell 16Carcinoma 16Non-Muscle Invasive Bladder Neoplasms 15

Interventions

Pemetrexed 2rofecoxib 1pembrolizumab 1paclitaxel poliglumex 1osimertinib 1aumolertinib 1atezolizumab 1anlotinib 1Radiosurgery 1RO5126766 1Nivolumab 1Gemcitabine 1Drug Therapy 1Cisplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Advanced Non-small Cell Lung Cancer × Gemcitabine × Clear all
NCT00385606 2023-03-23

Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced NSCLC

National Cancer Institute, Naples

Phase 2/3 Completed
400 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡